Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 16/20 | 0.89 |
| ▸ | MMP2 | P08253 | 13/20 | 0.89 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5191094 | 1.00 | MMP9 (0.89) | MMP9MMP2KCNA5MEN1POLB | |
| SCHEMBL7301154 | 0.94 | MMP9 (1.00) | MMP9MMP2KCNA5MEN1POLB | |
| SCHEMBL3154749 | 0.92 | MMP9 (0.88) | MMP9MMP2KCNA5MEN1POLB | |
| SCHEMBL8603495 | 0.92 | MMP9 (0.83) | MMP9MMP2KCNA5MEN1POLB | |
| SCHEMBL8839724 | 0.92 | MMP9 (0.94) | MMP9MMP2KCNA5MEN1POLB | |
| SCHEMBL7468980 | 0.92 | MMP9 (0.83) | MMP9MMP2KCNA5MEN1POLB | |
| SCHEMBL7468990 | 0.92 | MMP9 (0.83) | MMP9MMP2KCNA5MEN1POLB | |
| SCHEMBL22500298 | 0.92 | MMP9 (0.83) | MMP9MMP2KCNA5MEN1POLB | |
| SCHEMBL22500283 | 0.92 | MMP9 (0.83) | MMP9MMP2KCNA5MEN1POLB | |
| SCHEMBL13799679 | 0.92 | MMP9 (0.83) | MMP9MMP2KCNA5MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183236-B2 | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-02 | — | — | US | disclosed |
| US-4283337-A | Process for the purification of tryptophane and derivatives of tryptophane | DEUTSCHE GOLD UND- SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1981-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | TYMP, IMPDH1, SAMHD1 | MMP9 962/4885MMP2 1135/4885KCNA5 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.